Combatting infectious diseases; Nanotechnology as a platform for rational vaccine design

Advanced Drug Delivery Reviews

Volumn 74, Issue , 2014, Pages 28-34

  van Riet, Elly ^a,b   Ainai, Akira ^a   Suzuki, Tadaki ^a   Kersten, Gideon ^b,c   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Institute for Translational Vaccinology   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Adaptive immunity; Adjuvant; Administration route; Delivery; Innate immunity; Nanoparticle; Pathogen; Targeting

Indexed keywords

NANOPARTICLES; PATHOGENS; VACCINES;

ADAPTIVE IMMUNITY; ADJUVANT; DELIVERY; INNATE IMMUNITY; TARGETING;

VACCINES; DISEASES;

NANOPARTICLE; VACCINE;

CELLULAR IMMUNITY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MONITORING; HUMAN; HYDROPHOBICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURFACE CHARGE; SURFACE PROPERTY; DRUG TARGETING; IMMUNOREGULATION; ANIMAL; COMMUNICABLE DISEASE; IMMUNOLOGY; INFECTION CONTROL; PROCEDURES;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG DESIGN; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; VACCINES;

EID: 84905993471     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.05.011     Document Type: Review

References (78)

1. Rappuoli R., Miller H.I., Falkow S. Medicine. The intangible value of vaccination. Science 2002, 297:937-939.
2. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007, 298:2155-2163.
3. Julien J.P., Lee P.S., Wilson I.A. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol. Rev. 2012, 250:180-198.
4. Arens R. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors. Adv. Immunol. 2012, 114:217-243.
5. O'Donnell C.D., Vogel L., Wright A., Das S.R., Wrammert J., Li G.M., McCausland M., Zheng N.Y., Yewdell J.W., Ahmed R., Wilson P.C., Subbarao K. Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice. mBio 2012, 3.
6. Redford P.S., Murray P.J., O'Garra A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 2011, 4:261-270.
7. Coban C., Ishii K.J., Horii T., Akira S. Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol. 2007, 15:271-278.
8. Swartz M.A., Hirosue S., Hubbell J.A. Engineering approaches to immunotherapy. Sci. Transl. Med. 2012, 4(148):148rv9.
9. Allison A.G., Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974, 252:252.
10. Birrenbach G., Speiser P.P. Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci. 1976, 65:1763-1766.
11. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308:457-460.
12. Rueckert C., Guzman C.A. Vaccines: from empirical development to rational design. PLoS Pathog. 2012, 8:e1003001.
13. Hubbell J.A., Thomas S.N., Swartz M.A. Materials engineering for immunomodulation. Nature 2009, 462:449-460.
14. McKinstry K.K., Strutt T.M., Swain S.L. Hallmarks of CD4 T cell immunity against influenza. J. Intern. Med. 2011, 269:507-518.
15. Amorij J.P., Kersten G.F., Saluja V., Tonnis W.F., Hinrichs W.L., Slutter B., Bal S.M., Bouwstra J.A., Huckriede A., Jiskoot W. Towards tailored vaccine delivery: needs, challenges and perspectives. J. Control. Release 2012, 161:363-376.
16. De Groot A.S., Ardito M., Terry F., Levitz L., Ross T.M., Moise L., Martin W. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum. Vaccin. Immunother. 2013, 9.
17. He Y., Rappuoli R., De Groot A.S., Chen R.T. Emerging vaccine informatics. J. Biomed. Biotechnol. 2010, 2010:218590.
18. Fahy A.S., Clark R.H., Glyde E.F., Smith G.L. Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J. Gen. Virol. 2008, 89:2377-2387.
19. Moise L., Gutierrez A.H., Bailey-Kellogg C., Terry F., Leng Q., Abdel Hady K.M., Verberkmoes N.C., Sztein M.B., Losikoff P.T., Martin W.D., Rothman A.L., De Groot A.S. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 2013, 9.
20. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5:505-517.
21. Slutter B., Plapied L., Fievez V., Sande M.A., des Rieux A., Schneider Y.J., Van Riet E., Jiskoot W., Preat V. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 2009, 138:113-121.
22. Bal S.M., Ding Z., van Riet E., Jiskoot W., Bouwstra J.A. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?. J. Control. Release 2010, 148:266-282.
23. Zhu Q., Talton J., Zhang G., Cunningham T., Wang Z., Waters R.C., Kirk J., Eppler B., Klinman D.M., Sui Y., Gagnon S., Belyakov I.M., Mumper R.J., Berzofsky J.A. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat. Med. 2012, 18(8):1291-1296.
24. Cerutti A. The regulation of IgA class switching. Nat. Rev. Immunol. 2008, 8:421-434.
25. van Riet E., Ainai A., Suzuki T., Hasegawa H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine 2012, 30:5893-5900.
26. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat. Rev. Immunol. 2011, 11:221-230.
27. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 2013, 3:13.
28. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10:787-796.
29. Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomedicine 2012, 7:5577-5591.
30. Silva J.M., Videira M., Gaspar R., Preat V., Florindo H.F. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J. Control. Release 2013, 168:179-199.
31. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4:469-478.
32. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 2013, 12:13-30.
33. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 2007, 121:3-9.
34. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4930-4934.
35. Vacha R., Martinez-Veracoechea F.J., Frenkel D. Receptor-mediated endocytosis of nanoparticles of various shapes. Nano Lett. 2011, 11:5391-5395.
36. Niikura K., Matsunaga T., Suzuki T., Kobayashi S., Yamaguchi H., Orba Y., Kawaguchi A., Hasegawa H., Kajino K., Ninomiya T., Ijiro K., Sawa H. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano 2013, 7(5):3926-3938.
37. Jegerlehner A., Storni T., Lipowsky G., Schmid M., Pumpens P., Bachmann M.F. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 2002, 32:3305-3314.
38. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
39. Kanekiyo M., Wei C.J., Yassine H.M., McTamney P.M., Boyington J.C., Whittle J.R., Rao S.S., Kong W.P., Wang L., Nabel G.J. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013, 499(7456):102-106.
40. Savard C., Guerin A., Drouin K., Bolduc M., Laliberte-Gagne M.E., Dumas M.C., Majeau N., Leclerc D. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One 2011, 6:e21522.
41. van Kooyk Y., Unger W.W., Fehres C.M., Kalay H., Garcia-Vallejo J.J. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol. Immunol. 2013, 55(2):143-145.
42. Lunov O., Syrovets T., Loos C., Nienhaus G.U., Mailander V., Landfester K., Rouis M., Simmet T. Amino-functionalized polystyrene nanoparticles activate the NLRP3 inflammasome in human macrophages. ACS Nano 2011, 5:9648-9657.
43. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2002, 2:151-161.
44. Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 2012, 30:7652-7657.
45. Klechevsky E., Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann. N. Y. Acad. Sci. 2013, 1284:24-30.
46. Teunissen M.B., Haniffa M., Collin M.P. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design. Curr. Top. Microbiol. Immunol. 2012, 351:25-76.
47. Diebold S.S. Activation of dendritic cells by toll-like receptors and C-type lectins. Handb. Exp. Pharmacol. 2009, 3-30.
48. Ahlen G., Strindelius L., Johansson T., Nilsson A., Chatzissavidou N., Sjoblom M., Rova U., Holgersson J. Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses. PLoS One 2012, 7:e46959.
49. Chua B.Y., Johnson D., Tan A., Earnest-Silveira L., Sekiya T., Chin R., Torresi J., Jackson D.C. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012, 7:e47492.
50. Raghuwanshi D., Mishra V., Suresh M.R., Kaur K. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012, 30:7292-7299.
51. Ejaz A., Ammann C.G., Werner R., Huber G., Oberhauser V., Horl S., Schimmer S., Dittmer U., von Laer D., Stoiber H., Banki Z. Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One 2012, 7:e45102.
52. Cruz L.J., Tacken P.J., Pots J.M., Torensma R., Buschow S.I., Figdor C.G. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012, 33:4229-4239.
53. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., Lambeck A.J., Figdor C.G. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118:6836-6844.
54. Kamath A.T., Mastelic B., Christensen D., Rochat A.F., Agger E.M., Pinschewer D.D., Andersen P., Lambert P.H., Siegrist C.A. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 2012, 188:4828-4837.
55. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
56. Yoneyama M., Onomoto K., Fujita T. Cytoplasmic recognition of RNA. Adv. Drug Deliv. Rev. 2008, 60:841-846.
57. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
58. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
59. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316:612-616.
60. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17463-17468.
61. Cervi L., MacDonald A.S., Kane C., Dzierszinski F., Pearce E.J. Cutting edge: dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th1 and helminth-specific Th2 responses. J. Immunol. 2004, 172:2016-2020.
62. Guiducci C., Ott G., Chan J.H., Damon E., Calacsan C., Matray T., Lee K.D., Coffman R.L., Barrat F.J. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 2006, 203:1999-2008.
63. Keijzer C., Slutter B., van der Zee R., Jiskoot W., van Eden W., Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 2011, 6:e26684.
64. Kunisawa J., Nakagawa S., Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv. Drug Deliv. Rev. 2001, 52:177-186.
65. Budimir N., Meijerhof T., Wilschut J., Huckriede A., de Haan A. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine 2010, 28:8280-8287.
66. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
67. Johansen P., Mohanan D., Martinez-Gomez J.M., Kundig T.M., Gander B. Lympho-geographical concepts in vaccine delivery. J. Control. Release 2010, 148:56-62.
68. Johansen P., Men Y., Audran R., Corradin G., Merkle H.P., Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 1998, 15:1103-1110.
69. Boehm G., Peyre M., Sesardic D., Huskisson R.J., Mawas F., Douglas A., Xing D., Merkle H.P., Gander B., Johansen P. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm. Res. 2002, 19:1330-1336.
70. Plotkin S.A. Complex correlates of protection after vaccination. Clin. Infect. Dis. 2013, 56:1458-1465.
71. Srinivas M., Cruz L.J., Bonetto F., Heerschap A., Figdor C.G., de Vries I.J. Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials 2010, 31:7070-7077.
72. Primard C., Rochereau N., Luciani E., Genin C., Delair T., Paul S., Verrier B. Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells. Biomaterials 2010, 31:6060-6068.
73. Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012, 14:282-295.
74. McNeil S.E. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:264-271.
75. Yildirimer L., Thanh N.T., Loizidou M., Seifalian A.M. Toxicology and clinical potential of nanoparticles. Nano Today 2011, 6:585-607.
76. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., Zhou B., Lu H., Boddapati S., Li J., Flyer D., Glenn G. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012, 7:e50852.
77. Glenn G.M., Smith G., Fries L., Raghunandan R., Lu H., Zhou B., Thomas D.N., Hickman S.P., Kpamegan E., Boddapati S., Piedra P.A. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.
78. Gerdts V., Mutwiri G., Richards J., Hurk S.V., Potter A.A. Carrier molecules for use in veterinary vaccines. Vaccine 2013, 31(4):596-602.